vs
Apellis Pharmaceuticals, Inc.（APLS）与Orion Group Holdings Inc（ORN）财务数据对比。点击上方公司名可切换其他公司
Orion Group Holdings Inc的季度营收约是Apellis Pharmaceuticals, Inc.的1.1倍（$216.3M vs $199.9M），Orion Group Holdings Inc净利率更高（2.2% vs -29.5%，领先31.7%），Orion Group Holdings Inc同比增速更快（14.6% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 6.1%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
奥里昂集团是源自芬兰的全球化制药企业，1917年成立，总部位于芬兰埃斯波。公司面向全球市场研发、生产并销售人用与兽用药品以及药用活性成分，旗下全部生产基地与大部分研发部门均设立在芬兰。
APLS vs ORN — 直观对比
营收规模更大
ORN
是对方的1.1倍
$199.9M
营收增速更快
ORN
高出20.6%
-5.9%
净利率更高
ORN
高出31.7%
-29.5%
两年增速更快
APLS
近两年复合增速
6.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $216.3M |
| 净利润 | $-59.0M | $4.7M |
| 毛利率 | — | 12.0% |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 2.2% |
| 营收同比 | -5.9% | 14.6% |
| 净利润同比 | -62.2% | 435.7% |
| 每股收益（稀释后） | $-0.40 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSORN
| Q1 26 | — | $216.3M | ||
| Q4 25 | $199.9M | $233.2M | ||
| Q3 25 | $458.6M | $225.1M | ||
| Q2 25 | $178.5M | $205.3M | ||
| Q1 25 | $166.8M | $188.7M | ||
| Q4 24 | $212.5M | $216.9M | ||
| Q3 24 | $196.8M | $226.7M | ||
| Q2 24 | $199.7M | $192.2M |
净利润APLSORN
| Q1 26 | — | $4.7M | ||
| Q4 25 | $-59.0M | $-240.0K | ||
| Q3 25 | $215.7M | $3.3M | ||
| Q2 25 | $-42.2M | $841.0K | ||
| Q1 25 | $-92.2M | $-1.4M | ||
| Q4 24 | $-36.4M | $6.8M | ||
| Q3 24 | $-57.4M | $4.3M | ||
| Q2 24 | $-37.7M | $-6.6M |
毛利率APLSORN
| Q1 26 | — | 12.0% | ||
| Q4 25 | — | 11.6% | ||
| Q3 25 | — | 13.2% | ||
| Q2 25 | — | 12.6% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | — | 14.0% | ||
| Q3 24 | — | 11.9% | ||
| Q2 24 | — | 9.5% |
营业利润率APLSORN
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 2.2% | ||
| Q3 25 | 48.7% | 2.4% | ||
| Q2 25 | -18.6% | 1.7% | ||
| Q1 25 | -50.0% | 0.4% | ||
| Q4 24 | -12.3% | 4.4% | ||
| Q3 24 | -24.0% | 3.4% | ||
| Q2 24 | -14.7% | -1.4% |
净利率APLSORN
| Q1 26 | — | 2.2% | ||
| Q4 25 | -29.5% | -0.1% | ||
| Q3 25 | 47.0% | 1.5% | ||
| Q2 25 | -23.6% | 0.4% | ||
| Q1 25 | -55.3% | -0.7% | ||
| Q4 24 | -17.1% | 3.1% | ||
| Q3 24 | -29.2% | 1.9% | ||
| Q2 24 | -18.9% | -3.4% |
每股收益（稀释后）APLSORN
| Q1 26 | — | $0.12 | ||
| Q4 25 | $-0.40 | $-0.00 | ||
| Q3 25 | $1.67 | $0.08 | ||
| Q2 25 | $-0.33 | $0.02 | ||
| Q1 25 | $-0.74 | $-0.04 | ||
| Q4 24 | $-0.30 | $0.22 | ||
| Q3 24 | $-0.46 | $0.12 | ||
| Q2 24 | $-0.30 | $-0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $6.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $166.7M |
| 总资产 | $1.1B | $478.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSORN
| Q1 26 | — | $6.3M | ||
| Q4 25 | $466.2M | $1.6M | ||
| Q3 25 | $479.2M | $4.9M | ||
| Q2 25 | $370.0M | $1.7M | ||
| Q1 25 | $358.4M | $13.0M | ||
| Q4 24 | $411.3M | $28.3M | ||
| Q3 24 | $396.9M | $28.3M | ||
| Q2 24 | $360.1M | $4.8M |
总债务APLSORN
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $33.4M | ||
| Q1 25 | — | $23.3M | ||
| Q4 24 | — | $23.2M | ||
| Q3 24 | — | $28.0M | ||
| Q2 24 | — | $60.3M |
股东权益APLSORN
| Q1 26 | — | $166.7M | ||
| Q4 25 | $370.1M | $159.0M | ||
| Q3 25 | $401.2M | $157.9M | ||
| Q2 25 | $156.3M | $153.2M | ||
| Q1 25 | $164.2M | $150.8M | ||
| Q4 24 | $228.5M | $150.7M | ||
| Q3 24 | $237.1M | $142.4M | ||
| Q2 24 | $264.3M | $111.1M |
总资产APLSORN
| Q1 26 | — | $478.7M | ||
| Q4 25 | $1.1B | $414.7M | ||
| Q3 25 | $1.1B | $422.4M | ||
| Q2 25 | $821.4M | $432.7M | ||
| Q1 25 | $807.3M | $416.3M | ||
| Q4 24 | $885.1M | $417.3M | ||
| Q3 24 | $901.9M | $430.3M | ||
| Q2 24 | $904.5M | $414.0M |
负债/权益比APLSORN
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.22× | ||
| Q1 25 | — | 0.15× | ||
| Q4 24 | — | 0.15× | ||
| Q3 24 | — | 0.20× | ||
| Q2 24 | — | 0.54× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSORN
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $13.8M | ||
| Q3 25 | $108.5M | $23.3M | ||
| Q2 25 | $4.4M | $-5.6M | ||
| Q1 25 | $-53.4M | $-3.4M | ||
| Q4 24 | $19.4M | $13.4M | ||
| Q3 24 | $34.1M | $37.5M | ||
| Q2 24 | $-8.3M | $-15.3M |
自由现金流APLSORN
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $454.0K | ||
| Q3 25 | $108.3M | $13.9M | ||
| Q2 25 | $4.4M | $-12.7M | ||
| Q1 25 | $-53.4M | $-12.5M | ||
| Q4 24 | $19.3M | $9.9M | ||
| Q3 24 | — | $33.3M | ||
| Q2 24 | $-8.4M | $-20.0M |
自由现金流率APLSORN
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 0.2% | ||
| Q3 25 | 23.6% | 6.2% | ||
| Q2 25 | 2.5% | -6.2% | ||
| Q1 25 | -32.0% | -6.6% | ||
| Q4 24 | 9.1% | 4.6% | ||
| Q3 24 | — | 14.7% | ||
| Q2 24 | -4.2% | -10.4% |
资本支出强度APLSORN
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 5.7% | ||
| Q3 25 | 0.0% | 4.2% | ||
| Q2 25 | 0.0% | 3.5% | ||
| Q1 25 | 0.0% | 4.8% | ||
| Q4 24 | 0.0% | 1.6% | ||
| Q3 24 | 0.0% | 1.8% | ||
| Q2 24 | 0.0% | 2.4% |
现金转化率APLSORN
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 7.05× | ||
| Q2 25 | — | -6.61× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.98× | ||
| Q3 24 | — | 8.79× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
ORN
暂无分部数据
